Tissue Regenix Group (LON:TRX) appointed Kirsten Lund as its new finance director on Tuesday.
The regenerative medical devices group said that Lund has been promoted to finance director after nine years at the firm as financial controller, but will not be appointed to the board.
She will take up with immediate effect the responsibilities of the chief financial officer, Mike Barker, who has resigned from his position for personal reasons and will leave the company at the end of November.
John Samuel, executive chairman, called Lund an “excellent asset to the management team”, saying that her “knowledge and understanding of the business is invaluable as we look to drive the future growth of the company”.
Chartered accountant Barker leaves the group after being appointed in August, and having served two previous stints as interim chief financial officer.